Pharming (PHAR) Income towards Parent Company (2020 - 2026)
Pharming's (PHAR) quarterly Income towards Parent Company came in at -$10.3 million in Q2 2026, down 3.12% YoY from -$10.7 million in Q2 2025, and up 30.56% on a QoQ basis from -$14.9 million in Q1 2026.
Pharming (PHAR) Income towards Parent Company (2020 - 2026) Analysis & Trends
Pharming (PHAR) has 7 years of Income towards Parent Company data on file, last reported at -$10.3 million in Q2 2026.
- Quarterly Income towards Parent Company fell 3.12% year-over-year to -$10.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$39.9 million (down 60.26% YoY) and the FY2025 annual result came in at $2.9 million, up 124.08% from the prior year.
- Income towards Parent Company rose to -$10.3 million in Q2 2026, from -$14.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $28.3 million in Q4 2022 to a low of -$14.9 million in Q1 2025.
- A 5-year average of -$2.4 million and a median of -$11.05 in 2024 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company jumped 151.11% — and 2025, when it tumbled 1336363536.36%.
- Tracing PHAR's Income towards Parent Company over 5 years: stood at $28.3 million in 2022, then tumbled by 100.0% to -$7.4 in 2023, then sank by 98.65% to -$14.7 in 2024, then jumped by 136.05% to $5.3 in 2025, then sank by 195056703.77% to -$10.3 million in 2026.
- The last three Income towards Parent Company figures came in at -$10.3 million (Q2 2026), -$14.9 million (Q1 2026), and $5.3 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.34 Mn |
| Mar 31, 2026 | -14.89 Mn |
| Dec 31, 2025 | 5.30 |
| Sep 30, 2025 | -14.70 Mn |
| Jun 30, 2025 | -10.03 Mn |
| Mar 31, 2025 | -14.89 Mn |
| Dec 31, 2024 | -14.70 |
| Sep 30, 2024 | -1.10 |
| Jun 30, 2024 | -13.67 Mn |
| Mar 31, 2024 | -12.45 Mn |
| Dec 31, 2023 | -7.40 |
| Sep 30, 2023 | 3.46 Mn |
| Jun 30, 2023 | 1.30 |
| Mar 31, 2023 | -12.21 Mn |
| Dec 31, 2022 | 28.30 Mn |
| Sep 30, 2022 | 9.10 Mn |
| Jun 30, 2022 | 15.70 Mn |
| Mar 31, 2022 | 3.60 Mn |
| Dec 31, 2021 | 15.19 Mn |
| Sep 30, 2021 | -17.81 Mn |